Sanofi Tests mRNA Flu Vaccine That Could Outperform Traditional Shots
A Phase 1/2 trial evaluates whether an mRNA-based quadrivalent influenza vaccine can match or beat standard and high-dose comparators in adults.
Summary
Sanofi Pasteur conducted a Phase 1/2 clinical trial testing MRT5413, a quadrivalent influenza mRNA vaccine, in adults aged 18 and older. Participants received one of three dose levels via a single intramuscular injection, with results compared against standard-dose flu shots, high-dose flu shots (for those 65 and older), and a recombinant influenza vaccine. The trial assessed both safety — monitoring for adverse reactions — and immunogenicity, meaning how well the vaccine triggered an immune response. This study builds on the mRNA platform success seen with COVID-19 vaccines and asks whether that technology can now improve annual flu protection. If the mRNA flu vaccine proves safe and generates robust antibody responses, it could lead to more effective, faster-to-manufacture influenza vaccines in the future, benefiting especially older adults who respond poorly to conventional flu shots.
Detailed Summary
Seasonal influenza remains a significant public health burden, causing hundreds of thousands of hospitalizations and tens of thousands of deaths annually in the United States alone. Despite decades of vaccine development, standard-dose flu shots offer only modest protection, particularly in older adults whose immune systems respond less vigorously. The COVID-19 pandemic demonstrated that mRNA vaccine technology can be deployed rapidly and generate strong immune responses — raising the question of whether this platform could revolutionize influenza vaccination as well.
This completed Phase 1/2 trial, sponsored by Sanofi Pasteur and registered on ClinicalTrials.gov, evaluated MRT5413, a quadrivalent influenza mRNA vaccine targeting four influenza strains. Adults aged 18 and older received a single intramuscular injection of one of up to three dose levels of MRT5413. Comparators included a standard-dose quadrivalent inactivated vaccine, a high-dose quadrivalent inactivated vaccine (for participants aged 65 and older), and a quadrivalent recombinant influenza vaccine, allowing meaningful benchmarking across existing options.
The trial's dual primary objectives were safety — capturing solicited and unsolicited adverse events, serious adverse events, and local and systemic reactions — and immunogenicity, assessed through antibody titer measurements. Detailed results have not been published in the abstract; however, the completed status suggests data collection and analysis are finalized.
If MRT5413 demonstrates favorable immunogenicity alongside an acceptable safety profile, it could represent a meaningful advance in flu vaccine technology. The mRNA platform allows for rapid strain updates each season, potentially improving the match between vaccine and circulating viruses. For older adults, a potent mRNA flu vaccine could fill a critical gap left by existing high-dose options.
Caveats include the early phase design, which prioritizes safety and dose-finding over efficacy. Full immunogenicity and safety data have not yet been published in peer-reviewed literature, limiting definitive conclusions at this stage.
Key Findings
- MRT5413 mRNA flu vaccine was tested at up to 3 dose levels in adults 18+ in a Phase 1/2 trial.
- The trial compared MRT5413 against standard-dose, high-dose, and recombinant quadrivalent flu vaccines.
- Adults 65 and older were eligible for comparison against high-dose flu vaccine, the current gold standard for seniors.
- The trial is completed, suggesting safety and immunogenicity data are available but not yet fully published.
- mRNA flu vaccines could enable faster seasonal strain updates compared to traditional egg-based manufacturing.
Methodology
This was a Phase 1/2, multi-arm, active-controlled clinical trial enrolling adults 18 years and older, with older adults (65+) included in a high-dose comparator arm. Participants received a single intramuscular injection at one of up to three dose levels of MRT5413 or an active comparator vaccine. The trial was sponsored by Sanofi Pasteur and is now completed per ClinicalTrials.gov records.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full data have not been published in an accessible peer-reviewed paper. Specific immunogenicity endpoints and safety event rates are not yet available from public sources. As a Phase 1/2 trial, the study is designed for dose-finding and early safety, not definitive efficacy against influenza infection.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: